Filing Analysis
vTv Therapeutics Inc. filed an 8-K to announce its financial results for the fiscal quarter ended June 30, 2026. The filing serves as a formal announcement of the earnings release and does not contain specific material changes or distress indicators in the text provided.
📋 Key Facts
- Report date: August 6, 2026
- Reporting period ended June 30, 2026
- The filing is a standard announcement of quarterly financial results (Item 2.02)
- Exhibit 99.1 contains the full press release regarding financial performance
vTv Therapeutics Inc. held its 2026 Annual Meeting of Stockholders on June 26, 2026. The filing reports the election of seven directors and the ratification of Ernst & Young LLP as independent auditors.
🚩 Red Flags
- High number of 'Abstain' or 'Withheld' votes in the Say-on-Pay vote (1,967,329) compared to 'For' votes (686,535), suggesting significant shareholder dissatisfaction with executive compensation structures.
📋 Key Facts
- Annual Meeting held on June 26, 2026.
- Seven nominees were elected to the Board of Directors for terms expiring at the 2027 annual meeting.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Stockholders voted on a nonbinding advisory basis regarding executive compensation (Say-on-Pay), with significant abstentions/broker non-votes noted.
vTv Therapeutics Inc. announced its financial results for the first quarter ended March 31, 2026. The filing serves as a formal notice of the earnings release and includes the associated press release as an exhibit.
📋 Key Facts
- Announced financial results for the quarter ended March 31, 2026.
- Filed under Item 2.02 (Results of Operations and Financial Condition).
- Included Exhibit 99.1, the press release detailing the financial results.
- Signed by President and CEO Paul J. Sekhri on May 13, 2026.
vTv Therapeutics Inc. filed a prospectus supplement on May 13, 2026, to increase the number of shares of Class A common stock offered under its existing at-the-market (ATM) sales program. The company is moving to utilize the full amount provided for under the program to facilitate capital raising.
🚩 Red Flags
- Potential for significant shareholder dilution as the company maximizes its ATM issuance
- Frequent reliance on ATM programs in micro-cap biotech often signals a limited cash runway
📋 Key Facts
- Filed prospectus supplement on May 13, 2026
- Increased ATM Program shares to the full amount originally provided for
- Filed a legal opinion from Dechert LLP (Exhibit 5.1) regarding the legality of the shares
- The shares are being issued under an existing shelf Registration Statement on Form S-3
vTv Therapeutics Inc. has updated its investor presentation as of March 10, 2026, for use in upcoming meetings with investors and analysts. The presentation was filed under Regulation FD and is available as Exhibit 99.1.
📋 Key Facts
- Updated investor presentation posted to the company website on March 10, 2026
- The presentation will be used for meetings with analysts and other parties
- The filing is made under Item 7.01 Regulation FD Disclosure
- Exhibit 99.1 contains the full investor presentation dated March 2026
vTv Therapeutics Inc. announced its financial results for the fiscal year ended December 31, 2025, via a press release on March 10, 2026.
📋 Key Facts
- The company reported financial results for the fiscal year ended December 31, 2025
- The announcement was made through a press release dated March 10, 2026
- The filing was made under Item 2.02 (Results of Operations and Financial Condition)
vTv Therapeutics Inc. updated its corporate investor presentation on February 26, 2026, for use in upcoming meetings with investors and analysts. The presentation was filed as an exhibit to comply with Regulation FD requirements.
📋 Key Facts
- The company posted an updated slide presentation to its website on February 26, 2026.
- The presentation is intended for use in meetings with investors, analysts, and other parties.
- The filing was made under Item 7.01 (Regulation FD Disclosure) and includes Exhibit 99.1.
- The presentation is dated February 2026.
vTv Therapeutics LLC entered into a Second Amendment to its License Agreement with Newsoara Biopharma Co., Ltd. regarding the PDE4 inhibitor HPP737. The amendment expands Newsoara's global rights in exchange for an upfront payment and significant milestone/royalty potential.
🚩 Red Flags
- The filing notes that a previous amendment between the parties became 'null and void' in June 2025, suggesting prior instability in this specific licensing relationship.
📋 Key Facts
- Newsoara will pay a $20 million upfront fee to expand rights for HPP737 to all countries worldwide.
- The agreement includes up to $50 million in development milestones.
- The agreement includes up to $65 million in sales-related milestones and royalties.
- Royalties are expected to be in the mid single digits based on sales volumes.
- A previous amendment with Newsoara had become null and void in June 2025.
vTv Therapeutics Inc. amended its Second Amended and Restated By-Laws to reduce the quorum requirement for stockholder meetings.
🚩 Red Flags
- Reduction in quorum requirements can sometimes be used by management to push through actions with lower shareholder participation, though it is a common administrative change.
📋 Key Facts
- Amendment made on December 19, 2025.
- Amended Section 2.8 of Article II of the Company's Second Amended and Restated By-Laws.
- Quorum requirement for any meeting of stockholders reduced to 33.4%.
vTv Therapeutics Inc. filed an 8-K to announce its financial results for the fiscal quarter ended September 30, 2025.
📋 Key Facts
- Reporting period: Fiscal quarter ended September 30, 2025
- Filing date: November 6, 2025
- The filing includes a press release (Exhibit 99.1) detailing financial results.
vTv Therapeutics Inc. announced its participation in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025.
📋 Key Facts
- Company will participate in a fireside chat during the Morgan Stanley 23rd Annual Global Healthcare Conference.
- Event time: 2:35 PM - 3:10 PM EST on September 10, 2025.
- The session will be hosted via audio webcast and available on demand.
vTv Therapeutics Inc. entered into a securities purchase agreement for a private placement of 5,243,732 units to institutional investors, expected to raise approximately $80 million gross. The offering includes common stock, pre-funded warrants, and common warrants with specific exercise terms tied to clinical trial data.
🚩 Red Flags
- Warrant expiration tied to 'positive top-line data' creates significant potential dilution triggered by successful clinical outcomes.
- Pre-funded warrants with no expiration date can act as permanent dilutive overhang if not managed.
- Registration rights agreement includes liquidated damages (up to 3.0%) for failure to register securities in a timely manner.
📋 Key Facts
- Private placement of 5,243,732 units consisting of shares/pre-funded warrants and common warrants.
- Unit price: $15.265 for Units with Shares; $15.255 for Units with Pre-Funded Warrants.
- Expected gross proceeds: approximately $80 million (before expenses).
- Pre-funded warrants are exercisable for $0.01 and have no expiration date.
- Common warrants expire 5 years from issuance or 90 days after positive top-line data from the CATT1 clinical trial, whichever is earlier.
- Registration rights agreement requires a shelf registration statement to be filed within 30 days of closing.
vTv Therapeutics Inc. filed an 8-K to announce its financial results for the fiscal quarter ended June 30, 2025. The filing serves as a formal notice that a press release containing these results was issued on August 12, 2025.
📋 Key Facts
- The filing is related to the announcement of financial results for the fiscal period ended June 30, 2025.
- The official press release is attached as Exhibit 99.1.
- Report date: August 12, 2025.
vTv Therapeutics Inc. held its 2025 Annual Meeting of Stockholders on June 10, 2025. The meeting resulted in the election of seven directors and the ratification of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2025.
📋 Key Facts
- Annual Meeting held on June 10, 2025.
- Seven directors were elected: Srinivas Akkaraju, Raymond Cheong, Fahed Al Marzooqi, Richard S. Nelson, Anne Phillips, Paul Sekhri, and Daniel K. Spiegelman.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- The ratification of Ernst & Young received 2,400,291 votes 'For' and 3,852 votes 'Against'.
vTv Therapeutics Inc. announced the appointment of Michael Tung, M.D., MBA, as Executive Vice President and Chief Financial Officer, effective May 19, 2025.
📋 Key Facts
- Michael Tung appointed as EVP and CFO effective May 19, 2025.
- Tung holds an MD/MBA from Tufts University and is a licensed physician.
- Base salary is set at no less than $450,000 per year.
- Target annual cash bonus is 40% of base salary based on performance targets.
- Equity compensation includes 45,000 stock options with a 3-year vesting schedule (25% after one year).
- Employment agreement includes standard severance for termination without cause or resignation for good reason (9 months salary/COBRA).
vTv Therapeutics Inc. filed an 8-K to disclose a new investor presentation posted on its website as part of Regulation FD disclosure.
📋 Key Facts
- The company released an updated Investor Presentation dated May 2025 (Exhibit 99.1).
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
- The presentation will be used in meetings with investors and analysts.
vTv Therapeutics Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2025. The filing serves as a formal announcement of quarterly earnings via a press release.
📋 Key Facts
- Report date: May 15, 2025
- Reporting period: Fiscal quarter ended March 31, 2025
- The company issued a press release (Exhibit 99.1) to announce financial results.
- CEO Paul J. Sekhri signed the report.
vTv Therapeutics Inc. has appointed Barry K. Brown as interim Principal Financial Officer (PFO) effective April 11, 2025. Mr. Brown, the current Chief Accounting Officer, will serve in this capacity while the company conducts an external search for a permanent CFO.
🚩 Red Flags
- Leadership instability: The appointment of an 'interim' officer suggests a sudden vacancy or departure of the previous CFO.
- Recurrent interim status: Mr. Brown has previously held this interim role, indicating potential difficulty in attracting/retaining permanent financial leadership.
📋 Key Facts
- Barry K. Brown appointed as interim principal financial officer effective April 11, 2025.
- Mr. Brown currently serves as the Company's Chief Accounting Officer (since March 2022).
- Mr. Brown previously served as interim PFO from March 2022 to December 2022.
- Annual salary for the interim role remains at $231,000 per year.
- The company is actively conducting an external search for a permanent Chief Financial Officer.
vTv Therapeutics Inc. filed an 8-K to provide updated investor presentation materials via its website under Regulation FD disclosure.
📋 Key Facts
- The company posted an updated slide presentation on its website on March 31, 2025.
- The presentation is intended for use in meetings with investors, analysts, and other parties.
- Exhibit 99.1 contains the investor presentation dated March 2025.
vTv Therapeutics Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2024. The filing serves as a formal announcement of the company's annual earnings release.
📋 Key Facts
- Report date: March 20, 2025
- Reporting period: Fiscal year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) announcing financial results.
- The information is not considered 'filed' for purposes of Section 18 liability.
vTv Therapeutics announced that the FDA has lifted a clinical hold on its Cadisegliatin Program for Diabetes. This regulatory milestone allows the company to proceed with clinical development of this specific program.
📋 Key Facts
- FDA has officially lifted the clinical hold on the Cadisegliatin Program for Diabetes.
- The announcement was made via press release dated March 17, 2025.
- The filing is categorized under Item 8.01 (Other Events).
vTv Therapeutics Inc. announced that Steven Tuch, Executive Vice President and Chief Financial Officer, will resign effective March 21, 2025. The company is currently conducting an external search for a successor.
🚩 Red Flags
- Unexpected leadership turnover in a critical financial role (CFO) during the annual reporting cycle.
📋 Key Facts
- Steven Tuch to resign as EVP and CFO effective March 21, 2025.
- Departure date: February 24, 2025 (announced via filing).
- The CFO will remain through the filing of the FY2024 Annual Report on Form 10-K.
- Company has commenced an external search for a new CFO.
- The departure is not due to any disagreement with the Company or its independent auditors.
vTv Therapeutics Inc. filed an 8-K to disclose the posting of an updated investor slide presentation on its website under Regulation FD.
📋 Key Facts
- The company posted an updated investor presentation dated January 2025 (Exhibit 99.1).
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
- The information in the presentation is not deemed 'filed' for purposes of Section 18 liabilities.
vTv Therapeutics Inc. filed an 8-K to announce its financial results for the fiscal quarter ended September 30, 2024.
📋 Key Facts
- Report date: November 12, 2024
- Reporting period: Fiscal quarter ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) detailing financial results.
vTv Therapeutics' subsidiary received notice from OnKure Therapeutics of its intent to terminate a license agreement for the ppar-δ agonist program. The termination is due to OnKure deciding to discontinue development of the program and will be effective January 20, 2025.
🚩 Red Flags
- Loss of a licensed asset/program development partner
- Potential loss of future milestone or royalty payments associated with the ppar-δ agonist program
📋 Key Facts
- OnKure Therapeutics (formerly Reneo Pharmaceuticals) notified vTv LLC of intent to terminate the License Agreement dated December 21, 2017.
- The agreement granted OnKure an exclusive, worldwide license to intellectual property regarding the ppar-δ agonist program.
- Termination is scheduled to become effective on January 20, 2025.
- The decision by OnKure stems from their choice to discontinue development of the specific program.
vTv Therapeutics Inc. filed an 8-K to announce its financial results for the fiscal quarter ended June 30, 2024.
📋 Key Facts
- Report date: August 8, 2024
- Reporting period: Fiscal period ended June 30, 2024
- The filing serves to attach a press release (Exhibit 99.1) containing the quarterly financial results.
vTv Therapeutics Inc. announced that its Cadisegliatin program for the treatment of Type 1 Diabetes has been placed on clinical hold. This regulatory setback impacts a key therapeutic pipeline candidate.
🚩 Red Flags
- Clinical hold on a primary therapeutic program represents significant regulatory risk and potential delay in drug development timelines.
- Potential impact on investor sentiment regarding the company's clinical pipeline efficacy or safety profile.
📋 Key Facts
- The company's Cadisegliatin program for Type 1 Diabetes has been placed on clinical hold as of July 26, 2024.
- The announcement was made via a press release issued on July 26, 2024.
- The filing is an Item 8.01 (Other Events) disclosure.
vTv Therapeutics LLC entered into a Second Amendment to its License Agreement with Newsoara Biopharma Co., Ltd. to expand the license scope globally. The amendment includes an upfront fee of $20 million and significant milestone/royalty potential.
🚩 Red Flags
- The $20 million upfront fee is contingent upon payment within one year; if not paid, the amendment becomes null and void.
📋 Key Facts
- Date of agreement: June 26, 2024
- Counterparty: Newsoara Biopharma Co., Ltd.
- Upfront payment: $20 million (due within one year)
- Development milestones: Up to $41 million
- Sales-related milestones and royalties: Up to $35 million plus mid to upper single-digit royalties based on sales volume
- Scope change: Expansion from original terms to a global license
vTv Therapeutics Inc. held its 2024 Annual Meeting of Stockholders on June 11, 2024. The meeting resulted in the election of seven directors and the approval of the 2024 Equity Incentive Plan and the appointment of Ernst & Young LLP as independent auditors.
📋 Key Facts
- Annual Meeting held on June 11, 2024.
- Seven nominees elected to the Board of Directors: Srinivas Akkaraju, Raymond Cheong, Fahed Al Marzooqi, Richard S. Nelson, Anne Phillips, Paul Sekhri, and Daniel K. Spiegelman.
- Stockholders approved the adoption of the 2024 Equity Incentive Plan (1,814,842 votes 'For').
- Stockholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2024.
vTv Therapeutics Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly financial results (Item 2.02).
- Reporting period: Fiscal quarter ended March 31, 2024.
- Filing date: May 9, 2024.
vTv Therapeutics has regained compliance with Nasdaq's minimum market value requirement (Rule 5550(b)(2)). This resolves a previous deficiency that threatened the company's listing on the Nasdaq Capital Market.
🚩 Red Flags
- Previous non-compliance with minimum market value requirements indicates historical volatility and liquidity/valuation struggles.
📋 Key Facts
- Nasdaq notified the Company on March 25, 2024, that it has regained compliance with Listing Rule 5550(b)(2).
- The requirement involves maintaining a market value of listed securities (MVLS) at or above $35 million.
- As a result of regaining compliance, the Company's common stock will continue to be listed on the Nasdaq Capital Market.
vTv Therapeutics announced the election of Anne Phillips to the Board of Directors and her appointment as Chair of the Compensation Committee. The filing also confirms the resignations of directors John Fry and Howard Weiner, effective upon the filing of the 2023 Annual Report.
🚩 Red Flags
- Departure of two directors (John Fry and Howard Weiner) occurring simultaneously with the annual report filing.
📋 Key Facts
- Anne Phillips elected as director, effective March 13, 2024.
- Ms. Phillips appointed Chair of the Compensation Committee and member of the Audit Committee.
- Ms. Phillips is classified as an 'independent' director per Nasdaq rules.
- John Fry resigned from his director role, effective upon filing of the 2023 Annual Report.
- Howard Weiner resigned from his director role, effective upon filing of the 2023 Annual Report.
vTv Therapeutics Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023. The filing serves as a formal announcement of the company's annual earnings release.
📋 Key Facts
- Reporting date: March 13, 2024
- Fiscal period covered: Year ended December 31, 2023
- The filing includes Exhibit 99.1 containing the full press release of financial results.
vTv Therapeutics Inc. filed an 8-K to disclose the posting of an updated investor presentation on its website under Regulation FD.
📋 Key Facts
- The company posted an updated slide presentation dated March 2024 as Exhibit 99.1.
- The presentation is intended for use in meetings with investors, analysts, and other parties.
- The disclosure is made pursuant to Item 7.01 (Regulation FD Disclosure).
vTv Therapeutics entered into a $50 million 'at-the-market' (ATM) equity offering agreement with TD Cowen and reported a significantly depleted cash position of approximately $9.4 million as of year-end 2023.
🚩 Red Flags
- Extremely low cash runway: The reported $9.4M in cash is minimal for a biotech firm, suggesting imminent need for capital.
- Dilutive financing: The $50M ATM offering represents significant potential dilution to existing shareholders.
- Liquidity concerns: The combination of low cash and the immediate activation of an ATM program often signals urgent liquidity needs.
📋 Key Facts
- Entered into a Sales Agreement with TD Cowen, LLC on February 28, 2024.
- The ATM offering allows for the sale of Class A common stock up to an aggregate price of $50.0 million.
- TD Cowen will receive a 3.0% commission on gross proceeds.
- Preliminary cash and cash equivalents as of December 31, 2023, are estimated at approximately $9.4 million.
- The company terminated its previous ATM agreement with Cantor Fitzgerald & Co. on February 26, 2024.
vTv Therapeutics completed a $51.0 million private placement of Class A common stock and pre-funded warrants, which included significant changes to the company's governance structure and board composition. The deal grants lead purchasers rights to appoint three directors and mandates specific commercial efforts to generate gross proceeds from licensing or royalty agreements.
🚩 Red Flags
- Significant dilution via the issuance of nearly 3.85 million pre-funded warrants.
- Governance shift: Lead investors gain significant control through board designation rights and voting procedure requirements (requiring 5 directors for certain actions).
- Performance-linked obligations: The company is contractually obligated to pursue $30M in licensing/royalty revenue, which may pressure R&D focus.
- Multiple officer/director departures and appointments triggered by the financing.
- CEO compensation increase (salary + large bonus) occurring simultaneously with a major dilutive financing event.
📋 Key Facts
- Closed a private placement on February 27, 2024, raising approximately $51.0 million in gross proceeds.
- Issued 464,377 shares of Class A common stock at $11.81 per share.
- Issued pre-funded warrants to purchase up to 3,853,997 shares at an effective price of $11.80 per share.
- Lead Purchasers granted rights to designate three nominees to the Board of Directors.
- Company must use 'commercially reasonable efforts' to secure $\$30.0 million in gross proceeds from licensing/royalty agreements (excluding TTP 399).
- Purchasers have a right to purchase an additional $30.0 million of common stock in 18 months.
- CEO Paul Sekhri's base salary increased from $480,000 to $650,000, with a one-time bonus of $471,042.